# Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

> **NCT05792644** · NA · COMPLETED · sponsor: **Harbin Medical University** · enrollment: 15 (actual)

## Conditions studied

- ALK Phosphorylation

## Interventions

- **DRUG:** crizotinib for rearrangement-negative, high phosphorylated ALK patients

## Key facts

- **NCT ID:** NCT05792644
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05792644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05792644, "Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05792644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*